
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

March 2019

Commission File Number: 001-38067

**Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)**

**3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On March 20, 2019, and March 25, 2019, Verona Pharma plc issued press releases reporting the purchase of shares by its Chief Financial Officer, Mr. Piers Morgan (the Person Discharging Managerial Responsibilities ("PDMR") announcement, the ("PDMR Announcements")).

On March 22, 2019, the Company also issued a press release announcing its Annual Report and Accounts for the year ended December 31, 2018 and giving notice of the of the Annual General Meeting (the "AGM and Annual Report Press Release").

The PDMR Announcements are furnished herewith as Exhibits 1.1 and 1.2 to this Report on Form 6-K.

The AGM and Annual Report Press Release is furnished herewith as Exhibit 1.3 to this Report on Form 6-K.

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
1.1	PDMR Announcement March 20, 2019
1.2	PDMR Announcement March 25, 2019
1.3	AGM and Annual Report Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

VERONA PHARMA PLC

Date: March 26, 2019

By: /s/ Claire Poll

Name: Claire Poll

Title: Legal Counsel



PDMR Dealing

March 20, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 18, 2019, Mr. Piers Morgan, CFO of the Company, purchased 34,481 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 58 pence per Ordinary Share and a total purchase price of £19,999.98. Following the acquisition, Mr. Morgan will have an interest in the Company of 93,075 Ordinary Shares, representing 0.09% of the Company's issued share capital.

The purchase by Mr. Morgan follows the purchases made by the Company's Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Piers Morgan
2	Reason for the notification	
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	Piers Morgan purchased 34,481 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) : 58.00 pence per Ordinary Share Volume(s) : 34,481 Ordinary Shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	18 March 2019
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Tel: +44 (0) 20 7710 7600



PDMR Dealing

March 25, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 22, 2019, Mr. Piers Morgan, CFO of the Company, purchased 20,132 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 64 pence per Ordinary Share and a total purchase price of £12,884.48. Following the acquisition, Mr. Morgan will have an interest in the Company of 113,207 Ordinary Shares, representing 0.11% of the Company's issued share capital.

The purchase by Mr. Morgan brings the total purchases made by him this month to £32,884.46 and follows the purchases made by the Company's Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Piers Morgan
2	Reason for the notification	
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Verona Pharma plc
b)	LEI	213800EVI6O6J3TIAL06

4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 5 pence each GB00BYW2KH80
b)	Nature of the transaction	Piers Morgan purchased 34,481 Ordinary Shares
c)	Price(s) and volume(s)	Price(s) : 64.00 pence per Ordinary Share Volume(s) : 20,132 Ordinary Shares
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	22 March 2019
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Verona Pharma plc
Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications
Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)
Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0)20 3283 4200
info@veronapharma.com

Tel: +44 (0) 20 7710 7600



Verona Pharma

**2018 Annual Report and Accounts
and
Notice of AGM**

March 22, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, is pleased to confirm that a hard copy of the Annual Report and Accounts for the year ended 31 December 2018 ("2018 Annual Report and Accounts"), the Notice of Annual General Meeting and a Form of Proxy have been posted to Shareholders.

The Company confirms that a copy of its 2018 Annual Report and Accounts and Notice of Annual General Meeting are available online at www.veronapharma.com. The Notice of Annual General Meeting can also be found within the AIM Rule 26 section of the website.

The Annual General Meeting of Verona Pharma will be held at the London offices of Latham & Watkins LLP, 99 Bishopsgate, London EC2M 3XF at 10.00 a.m. on 7 May 2019.

-Ends-

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, ensifentrine, is an investigational first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that is designed to act as both a bronchodilator and an anti-inflammatory agent in a single compound. Ensifentrine has been studied via the nebulized route of administration in clinical trials involving more than 800 subjects. The nebulized formulation of ensifentrine has significantly improved lung function, including enhanced peak FEV₁, reduced lung hyperinflation and faster onset-of-action when used alone or as an add-on treatment to some of the most commonly used COPD therapies, including tiotropium (Spiriva®), tiotropium/olodaterol fixed-dose combination, ipratropium, and albuterol. In addition, ensifentrine has shown anti-inflammatory effects in a standard challenge study with COPD-like inflammation in humans. Ensifentrine was well tolerated in these trials. Verona Pharma is developing ensifentrine for the treatment of COPD, cystic fibrosis and asthma.

For further information, please contact:

Verona Pharma plc

Jan-Anders Karlsson, Chief Executive Officer
Victoria Stewart, Director of Communications

Tel: +44 (0)20 3283 4200
info@veronapharma.com

**Stifel Nicolaus Europe Limited (Nominated Adviser
and UK Broker)**

Stewart Wallace / Jonathan Senior / Ben Maddison

Tel: +44 (0) 20 7710 7600

FTI Consulting (UK Media and Investor enquiries)
Simon Conway / Natalie Garland-Collins

Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)

Darcie Robinson

Tel: +1 203-919-7905
Darcie.Robinson@icrinc.com

Stephanie Carrington

Tel. +1 646-277-1282
Stephanie.Carrington@icrinc.com